S&P 500   2,997.95 (+0.28%)
DOW   27,025.88 (+0.09%)
QQQ   193.41 (+0.19%)
AAPL   234.33 (-0.02%)
FB   189.67 (+0.06%)
MSFT   139.47 (-0.67%)
GOOGL   1,253.85 (+0.87%)
AMZN   1,790.38 (+0.73%)
CGC   20.31 (+2.94%)
NVDA   192.60 (-0.83%)
MU   45.44 (+0.62%)
BABA   176.24 (-0.50%)
GE   9.07 (+1.80%)
TSLA   262.42 (+1.03%)
AMD   31.02 (+0.68%)
T   37.78 (-0.03%)
F   9.10 (+0.33%)
ACB   3.80 (+5.27%)
PRI   123.96 (+0.07%)
NFLX   293.35 (+2.47%)
BAC   30.07 (-0.33%)
GILD   65.16 (-0.29%)
DIS   132.86 (+1.53%)
S&P 500   2,997.95 (+0.28%)
DOW   27,025.88 (+0.09%)
QQQ   193.41 (+0.19%)
AAPL   234.33 (-0.02%)
FB   189.67 (+0.06%)
MSFT   139.47 (-0.67%)
GOOGL   1,253.85 (+0.87%)
AMZN   1,790.38 (+0.73%)
CGC   20.31 (+2.94%)
NVDA   192.60 (-0.83%)
MU   45.44 (+0.62%)
BABA   176.24 (-0.50%)
GE   9.07 (+1.80%)
TSLA   262.42 (+1.03%)
AMD   31.02 (+0.68%)
T   37.78 (-0.03%)
F   9.10 (+0.33%)
ACB   3.80 (+5.27%)
PRI   123.96 (+0.07%)
NFLX   293.35 (+2.47%)
BAC   30.07 (-0.33%)
GILD   65.16 (-0.29%)
DIS   132.86 (+1.53%)
Log in

Editas Medicine Stock Price, News & Analysis (NASDAQ:EDIT)

$20.21
-0.19 (-0.93 %)
(As of 10/17/2019 04:00 PM ET)
Today's Range
$20.19
Now: $20.21
$20.56
50-Day Range
$19.36
MA: $23.24
$26.62
52-Week Range
$17.80
Now: $20.21
$32.46
Volume158,813 shs
Average Volume783,262 shs
Market Capitalization$1.00 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.49
Editas Medicine, Inc operates as a clinical stage genome editing company. The company focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary genome editing platform based on CRISPR technology to target genetically addressable diseases and therapeutic areas. The company develops EDIT-101 for Leber Congenital Amaurosis type 10, a genetic form of vision loss that leads to blindness in childhood. Read More…

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:EDIT
CUSIPN/A
Phone617-401-9000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$31.94 million
Book Value$4.94 per share

Profitability

Net Income$-109,950,000.00
Net Margins-412.70%

Miscellaneous

Employees133
Market Cap$1.00 billion
Next Earnings Date11/6/2019 (Estimated)
OptionableOptionable

Receive EDIT News and Ratings via Email

Sign-up to receive the latest news and ratings for EDIT and its competitors with MarketBeat's FREE daily newsletter.


Editas Medicine (NASDAQ:EDIT) Frequently Asked Questions

What is Editas Medicine's stock symbol?

Editas Medicine trades on the NASDAQ under the ticker symbol "EDIT."

How were Editas Medicine's earnings last quarter?

Editas Medicine Inc (NASDAQ:EDIT) issued its quarterly earnings data on Tuesday, August, 6th. The company reported ($0.69) EPS for the quarter, missing analysts' consensus estimates of ($0.59) by $0.10. The company had revenue of $2.33 million for the quarter, compared to the consensus estimate of $6.88 million. Editas Medicine had a negative return on equity of 47.46% and a negative net margin of 412.70%. The business's revenue for the quarter was down 68.4% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.82) earnings per share. View Editas Medicine's Earnings History.

When is Editas Medicine's next earnings date?

Editas Medicine is scheduled to release their next quarterly earnings announcement on Wednesday, November 6th 2019. View Earnings Estimates for Editas Medicine.

What price target have analysts set for EDIT?

8 equities research analysts have issued 12 month target prices for Editas Medicine's shares. Their forecasts range from $29.00 to $55.00. On average, they anticipate Editas Medicine's stock price to reach $38.00 in the next year. This suggests a possible upside of 88.0% from the stock's current price. View Analyst Price Targets for Editas Medicine.

What is the consensus analysts' recommendation for Editas Medicine?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Editas Medicine in the last year. There are currently 3 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Editas Medicine.

What are Wall Street analysts saying about Editas Medicine stock?

Here are some recent quotes from research analysts about Editas Medicine stock:
  • 1. Chardan Capital analysts commented, "We anticipate better visibility around potential timing of data readouts as dosing gets underway. Below, we highlight thoughts on what we know of the program thus far." (7/25/2019)
  • 2. According to Zacks Investment Research, "Editas Medicine, Inc. is a genome editing company. It focuses on translating its genome editing technology into a novel class of human therapeutics which enable precise and corrective molecular modification to treat diseases. Editas Medicine, Inc. is based in Cambridge, Massachusetts. " (5/10/2019)

Has Editas Medicine been receiving favorable news coverage?

Media headlines about EDIT stock have trended somewhat negative on Thursday, according to InfoTrie. The research firm scores the sentiment of media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Editas Medicine earned a media sentiment score of -1.9 on InfoTrie's scale. They also gave headlines about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the company's share price in the next several days. View News Stories for Editas Medicine.

Who are some of Editas Medicine's key competitors?

What other stocks do shareholders of Editas Medicine own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Editas Medicine investors own include Crispr Therapeutics (CRSP), NVIDIA (NVDA), Micron Technology (MU), Intellia Therapeutics (NTLA), Alibaba Group (BABA), TransEnterix (TRXC), Portola Pharmaceuticals (PTLA), CA (CA), Shopify (SHOP) and Canopy Growth (CGC).

Who are Editas Medicine's key executives?

Editas Medicine's management team includes the folowing people:
  • Dr. Charles Albright, Chief Scientific Officer (Age 61)
  • Ms. Cynthia L. Collins, Interim CEO & Director (Age 61)
  • Dr. Feng Zhang, Co-Founder & Scientific Advisory Board Member
  • Dr. George M. Church, Co-Founder & Scientific Advisory Board Member (Age 65)
  • Dr. J. Keith Joung, Co-Founder & Scientific Advisory Board Member

When did Editas Medicine IPO?

(EDIT) raised $100 million in an IPO on Wednesday, February 3rd 2016. The company issued 5,900,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley and J.P. Morgan acted as the underwriters for the IPO and Cowen and Company and JMP Securities were co-managers.

How do I buy shares of Editas Medicine?

Shares of EDIT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Editas Medicine's stock price today?

One share of EDIT stock can currently be purchased for approximately $20.21.

How big of a company is Editas Medicine?

Editas Medicine has a market capitalization of $1.00 billion and generates $31.94 million in revenue each year. The company earns $-109,950,000.00 in net income (profit) each year or ($2.33) on an earnings per share basis. Editas Medicine employs 133 workers across the globe.View Additional Information About Editas Medicine.

What is Editas Medicine's official website?

The official website for Editas Medicine is http://www.editasmedicine.com/.

How can I contact Editas Medicine?

Editas Medicine's mailing address is 11 Hurley Street, Cambridge MA, 02141. The company can be reached via phone at 617-401-9000 or via email at [email protected]


MarketBeat Community Rating for Editas Medicine (NASDAQ EDIT)

Community Ranking:  2.1 out of 5 (star star)
Outperform Votes:  234 (Vote Outperform)
Underperform Votes:  315 (Vote Underperform)
Total Votes:  549
MarketBeat's community ratings are surveys of what our community members think about Editas Medicine and other stocks. Vote "Outperform" if you believe EDIT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EDIT will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/17/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel